Alliqua, Inc. is a biomedical company. The company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies. Its technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers. Alliqua BioMedical Inc - ALQA - Stock forecast - 3 months ... Adynxx Inc., formerly Alliqua BioMedical, Inc., is a clinical stage biopharmaceutical company. The Company is focused on development of non-opioid therapeutics for the treatment of pain and Celularity, Inc., Accelerates Breakthrough Placental Discovery and Therapeutic Platform ALQA Institutional Ownership - Alliqua, Inc. Stock ADYX / Adynxx, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 5 TO SCHEDULE 13G Passive Investment. 2019-02-14 sec.gov - 2 - Amendment No. 5 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Alliqua BioMedical, Inc. (Name of Issuer) Common Stock, …
In a report released today, Glenn Novarro from RBC Capital reiterated a Buy rating on Alliqua (NASDAQ: ALQA), with a price target of $6. The company's shares closed yesterday at $2.78, close to its 52-week low of $2.75. Alliqua has an analyst consensus of Moderate Buy. The company has a one year high of $6.55 and a one year low of $2.75. 4 Alliqua BioMedical reviews. A free inside look at company reviews and salaries posted anonymously by employees.
Alliqua BioMedical Inc. and Adynxx, Inc. Announce Merger Agreement to Create NASDAQ-listed Clinical-Stage Pharmaceutical Company with a Focus on Pain and Inflammation News provided by Adynxx, Inc. ALQA - Alliqua Biomedical Stock Price - Barchart.com Alliqua, Inc. is a biomedical company. The company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies. Its technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers. Alliqua BioMedical Inc - ALQA - Stock forecast - 3 months ... Adynxx Inc., formerly Alliqua BioMedical, Inc., is a clinical stage biopharmaceutical company. The Company is focused on development of non-opioid therapeutics for the treatment of pain and Celularity, Inc., Accelerates Breakthrough Placental Discovery and Therapeutic Platform ALQA Institutional Ownership - Alliqua, Inc. Stock ADYX / Adynxx, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 5 TO SCHEDULE 13G Passive Investment. 2019-02-14 sec.gov - 2 - Amendment No. 5 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Alliqua BioMedical, Inc. (Name of Issuer) Common Stock, …
Alliqua BioMedical, Inc. | 1,318 followers on LinkedIn | Alliqua BioMedical (NASDAQ: ALQA) develops and manufactures electron-beam cross-linked sheet gels for customers that include manufacturers 10-K: ALLIQUA BIOMEDICAL, INC. - MarketWatch Feb 22, 2019 Alliqua BioMedical, Inc., 1010 Stony Hill Road, Suite 200 ... Alliqua BioMedical is a functional regeneration company. Alliqua BioMedical (NASDAQ: ALQA) is a functional regeneration company, building a suite of technological solutions that allow clinicians to utilize the latest advances in regenerative therapies to bring improved patient outcomes to their practices. Alliqua Biomedical Inc. Archives - Stock News Union Jul 10, 2017
Alliqua BioMedical, Inc. (NASDAQ:ALQA) belonging to the Medical sector has surged 27.27% and closed its last trading session at $0.7. The company reported its EPS on 02/28/2017. Currently, the stock has a 1 Year Price Target of $2.25. The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong LANGHORNE, Pa. & SAN FRANCISCO, October 12, 2018 — Alliqua BioMedical, Inc. (Nasdaq:ALQA) and Adynxx, Inc., a privately held biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which the stockholders of Adynxx would become the majority owners of Alliqua's outstanding common stock on a fully-diluted basis. YARDLEY, Pa., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (NASDAQ:ALQA) ("Alliqua or the "Company"), a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced that the Company will effect a reverse stock split of its issued and outstanding common stock at an exchange ratio of 1 alliqua biomedical, inc. - contract (may 9th, 2019) this warrant and the shares issuable hereunder have not been registered under the securities act of 1933, as amended (the "act"), or the securities laws of any state and, except as set forth in section 5.3 below, may not be offered, sold, pledged or otherwise transferred unless and until registered under said act and laws or, in the Alliqua Biomedical, Inc. is an Alabama Foreign Corporation filed on April 10, 2014. The company's filing status is listed as Exists and its File Number is 306-989. The Registered Agent on file for this company is Csc-Lawyers Incorporating Srvc Inc and is located at 150 South Perry Street, Montgomery, AL 36104.